CLINICAL TRIALS HAVE A DIVERSITY PROBLEM.

CLINICAL TRIALS HAVE
A DIVERSITY PROBLEM.

That's why we're taking action
to make research more inclusive.

The concept is at the very core of everything we do: the best health care products are those that help the most people by providing the greatest benefit. Those products should result from clinical trials that include the diverse and representative populations who need them most. It sounds simple, but it’s not. The fact is that while people of diverse ethnic and cultural backgrounds make up nearly 40% of the U.S. population -- and are disproportionally impacted by chronic conditions like diabetes and cardiovascular disease, they are still heavily under-represented in the clinical trials process. Women are likewise under-represented.

 

These gaps exacerbate existing health equity challenges by curbing access to life-changing and life-saving treatments for some, while limiting insights into how different groups respond to new therapies. So we are doing something to close those gaps. Right now. By launching an initiative to drive diversity in research and improve care among under-represented populations, we are working to advance health equity and make access a crucial aspect of product innovation, two key aspects of Abbott's 2030 Sustainability Program. The medical therapies we develop can only be as strong and inclusive as the people who design, develop and participate in our clinical trials. Their involvement will benefit all.

 

 

 

I NEED TO BE ABLE TO LOOK MY PATIENTS IN THE EYE.

HEAR IT FROM
THE PEOPLE
WHO KNOW

WHY DIVERSITY IN CLINICAL
TRIALS IS IMPORTANT FOR
UNDERREPRESENTED POPULATIONS.

SCHOLARSHIPS SUPPORT  DIVERSE RESEARCHERS  OF THE FUTURE

SCHOLARSHIPS SUPPORT
DIVERSE RESEARCHERS
OF THE FUTURE

$5 MILLION OVER NEXT FIVE YEARS WILL CREATE
NEARLY 300 SCHOLARSHIPS FOR HBCUs AND
MINORITY NURSING ASSOCIATIONS.

CASE STUDY: CLINICAL TRIAL  DIVERSITY FOR LIFE-BTK

CASE STUDY: CLINICAL TRIAL
DIVERSITY FOR LIFE-BTK

NEIGHBORHOODS WITH THE HIGHEST AMPUTATION
RATES WERE REDLINED DURING SEGREGATION.

A Q&A WITH  DR. JOSEPH RAVENELL

A Q&A WITH
DR. JOSEPH RAVENELL

BREAKING DOWN BARRIERS TO ACHIEVE MORE
DIVERSE REPRESENTATION IN CLINICAL TRIALS.

Connect with Us
Contact Us

 

 

RESOURCES

"Clinical Trials Have a Diversity Problem."  FDA Encourages More Participation, Diversity in Clinical Trials | FDA

"Less than 5% of participants are hispanic" Lack of Latino Representation in Health Studies and Clinical Trials Could Have Negative Impacts, Advocates Say - Latino USA

"Less than 8% of participants are black"  Drug Trials Snapshots | FDA

"In cardio trials less than 34% of participants are women" https://www.jacc.org/doi/full/10.1016/j.jacc.2018.02.069

"In cardio trials less than 2.5% of participants are black" 2015-2016 Global Participation in Clinical Trials Report (fda.gov)

true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website??